Nanovaccine administration route is critical to obtain pertinent iNKt cell help for robust anti-tumor T and B cell responses

References

• Kinjo Y, Wu D, Kim G, Xing GW, Poles MA, Ho DD, Tsuji, M, Kawahara, K, Wong, CH, Kronenberg, M Recognition of bacterial glycosphingolipids by natural killer T cells. Nature. 2005;434:520–14. doi:10.1038/nature03407.
   PubMed Web of Science ®Google Scholar
• Lee YJ, Holzapfel KL, Zhu J, Jameson SC, Hogquist KA. Steady-state production of IL-4 modulates immunity in mouse strains and is determined by lineage diversity of iNKT cells. Nat Immunol. 2013;14(11):1146. doi:10.1038/ni.2731.
   PubMed Web of Science ®Google Scholar
• Smyth MJ, Wallace ME, Nutt SL, Yagita H, Godfrey DI, Hayakawa Y. Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer. J Exp Med. 2005;201(12):1973–1985. doi:10.1084/jem.20042280.
   PubMed Web of Science ®Google Scholar
• Neparidze N, Dhodapkar MV. Harnessing CD1d-restricted T cells toward antitumor immunity in humans. Ann N Y Acad Sci. 2009;1174(1):61–67. doi:10.1111/j.1749-6632.2009.04931.x.
   PubMedGoogle Scholar
• Brennan PJ, Brigl M, Brenner MB. Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions. Nat Rev Immunol. 2013;13(2):101. doi:10.1038/nri3369.
   PubMed Web of Science ®Google Scholar
• Cerundolo V, Silk JD, Masri SH, Salio M. Harnessing invariant NKT cells in vaccination strategies. Nat Rev Immunol. 2009;9:28–38. doi:10.1038/nri2451.
   PubMed Web of Science ®Google Scholar
• Jukes JP, Gileadi U, Ghadbane H, Yu TF, Shepherd D, Cox LR, Besra GS, Cerundolo V. Non-glycosidic compounds can stimulate both human and mouse iNKT cells. Eur J Immunol. 2016;46:1224–1234. doi:10.1002/eji.201546114.
   PubMed Web of Science ®Google Scholar
• Dolen Y, Kreutz M, Gileadi U, Tel J, Vasaturo A, van Dinther EA, van Hout-kuijer MA, Cerundolo V, Figdor CG. Co-delivery of PLGA encapsulated invariant NKT cell agonist with antigenic protein induce strong T cell-mediated antitumor immune responses. Oncoimmunology. 2016;5(1):e1068493. doi:10.1080/2162402X.2015.1068493.
   PubMed Web of Science ®Google Scholar
• Macho-Fernandez E, Cruz LJ, Ghinnagow R, Fontaine J, Bialecki E, Frisch B, Trottein F, Faveeuw C. Targeted delivery of alpha-galactosylceramide to CD8alpha+ dendritic cells optimizes type I NKT cell-based antitumor responses. J Immunol. 2014;193:961–969. doi:10.4049/jimmunol.1303029.
   PubMed Web of Science ®Google Scholar
• Hermans IF, Silk JD, Gileadi U, Salio M, Mathew B, Ritter G, Schmidt R, Harris AL, Old L, Cerundolo V, et al. NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. J Immunol. 2003;171:5140–5147. doi:10.4049/jimmunol.171.10.5140.
   PubMed Web of Science ®Google Scholar
• Crosby CM, Kronenberg M. Tissue-specific functions of invariant natural killer T cells. Nat Rev Immunol. 2018;18(9):559–574. doi:10.1038/s41577-018-0034-2.
   PubMed Web of Science ®Google Scholar
• Doisne J-M, Becourt C, Amniai L, Duarte N, Le Luduec J-B, Eberl G, Benlagha K. Skin and peripheral lymph node invariant NKT cells are mainly retinoic acid receptor-related orphan receptor γt+ and respond preferentially under inflammatory conditions. J Immunol. 2009;183:2142–2149. doi:10.4049/jimmunol.0901059.
   PubMed Web of Science ®Google Scholar
• King LA, Lameris R, de Gruijl TD, van der Vliet HJ. CD1d-invariant natural killer T cell-based cancer immunotherapy: alpha-galactosylceramide and beyond. Front Immunol. 2018;9:1519. doi:10.3389/fimmu.2018.01519.
   PubMed Web of Science ®Google Scholar
• Nicol AJ, Tazbirkova A, Nieda M. Comparison of clinical and immunological effects of intravenous and intradermal administration of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells. Clin Cancer Res. 2011;17:5140–5151. doi:10.1158/1078-0432.CCR-10-3105.
   PubMed Web of Science ®Google Scholar
• Nagaraj S, Ziske C, Strehl J, Messmer D, Sauerbruch T, Schmidt-Wolf IG. Dendritic cells pulsed with alpha-galactosylceramide induce anti-tumor immunity against pancreatic cancer in vivo. Int Immunol. 2006;18:1279–1283. doi:10.1093/intimm/dxl059.
   PubMed Web of Science ®Google Scholar
• Yoshiga Y, Goto D, Segawa S, Horikoshi M, Hayashi T, Matsumoto I, Ito S, Taniguchi M, Sumida T. Activation of natural killer T cells by alpha-carba-GalCer (RCAI-56), a novel synthetic glycolipid ligand, suppresses murine collagen-induced arthritis. Clin Exp Immunol. 2011;164:236–247. doi:10.1111/cei.2011.164.issue-2.
   PubMed Web of Science ®Google Scholar
• Lindqvist M, Persson J, Thorn K, Harandi AM. The mucosal adjuvant effect of alpha-galactosylceramide for induction of protective immunity to sexually transmitted viral infection. J Immunol. 2009;182:6435–6443. doi:10.4049/jimmunol.0900136.
   PubMed Web of Science ®Google Scholar
• Courtney AN, Thapa P, Singh S, Wishahy AM, Zhou D, Sastry J. Intranasal but not intravenous delivery of the adjuvant alpha-galactosylceramide permits repeated stimulation of natural killer T cells in the lung. Eur J Immunol. 2011;41:3312–3322. doi:10.1002/eji.201041359.
   PubMed Web of Science ®Google Scholar
• Bontkes HJ, Moreno M, Hangalapura B, Lindenberg JJ, de Groot J, Lougheed S, van der Vliet HJJ, van den Eertwegh AJM, de Gruijl TD, von Blomberg BME, et al. Attenuation of invariant natural killer T-cell anergy induction through intradermal delivery of alpha-galactosylceramide. Clin Immunol. 2010;136:364–374. doi:10.1016/j.clim.2010.04.019.
   PubMed Web of Science ®Google Scholar
• Slauenwhite D, Johnston B. Regulation of NKT Cell Localization in Homeostasis and Infection. Front Immunol. 2015;6:255. doi:10.3389/fimmu.2015.00255.
   PubMed Web of Science ®Google Scholar
• Hasegawa H, Yamashita K, Otsubo D, Kakeji Y. Liver Injury After Invariant NKT Cell Activation by Free Alpha-galactosylceramide and Alpha-galactosylceramide-loaded Dendritic Cells. Anticancer Res. 2016;36:3667–3672.
   PubMed Web of Science ®Google Scholar
• Barral P, Eckl-Dorna J, Harwood NE, De Santo C, Salio M, Illarionov P, Besra GS, Cerundolo V, Batista FD. B cell receptor-mediated uptake of CD1d-restricted antigen augments antibody responses by recruiting invariant NKT cell help in vivo. Proc Natl Acad Sci U S A. 2008;105(24):8345–8350. doi:10.1073/pnas.0802968105.
   PubMed Web of Science ®Google Scholar
• Wilson MT, Johansson C, Olivares-Villagomez D, Singh AK, Stanic AK, Wang C-R, Joyce S, Wick MJ, Van Kaer L. The response of natural killer T cells to glycolipid antigens is characterized by surface receptor down-modulation and expansion. Proc Natl Acad Sci U S A. 2003;100(19):10913–10918. doi:10.1073/pnas.1833166100.
   PubMed Web of Science ®Google Scholar
• Parekh VV, Wilson MT, Olivares-Villagomez D, Singh AK, Wu L, Wang CR, Joyce S, Van Kaer L. Glycolipid antigen induces long-term natural killer T cell anergy in mice. J Clin Invest. 2005;115:2572–2583. doi:10.1172/JCI24762.
   PubMed Web of Science ®Google Scholar
• Carnaud C, Lee D, Donnars O, Park S-H, Beavis A, Koezuka Y, Bendelac A. Cutting edge: cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J Immunol. 1999;163:4647–4650.
   PubMed Web of Science ®Google Scholar
• Kitamura H, Ohta A, Sekimoto M, Sato M, Iwakabe K, Nakui M, Yahata T, Meng H, Koda T, Nishimura S-I, et al. alpha-galactosylceramide induces early B-cell activation through IL-4 production by NKT cells. Cell Immunol. 2000;199:37–42. doi:10.1006/cimm.1999.1602.
   PubMed Web of Science ®Google Scholar
• Bartkowiak T, Singh S, Yang G, Galvan G, Haria D, Ai M, Allison JP, Sastry KJ, Curran MA. Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccine. Proc Natl Acad Sci U S A. 2015;112(38):E5290–9. doi:10.1073/pnas.1514418112.
   PubMed Web of Science ®Google Scholar
• Gasser O, Sharples KJ, Barrow C, Williams GM, Bauer E, Wood CE, Mester, B, Dzhelali, M, Caygill, G, Jones, J, et al. A phase I vaccination study with dendritic cells loaded with NY-ESO-1 and alpha-galactosylceramide: induction of polyfunctional T cells in high-risk melanoma patients. Cancer Immunol Immunother. 2018. ; 67:285–98.
   PubMed Web of Science ®Google Scholar
• Giaccone G, Punt CJ, Ando Y, Ruijter R, Nishi N, Peters M, von Blomberg BME, Scheper RJ, van der Vliet HJJ, van den Eertwegh AJM, et al. A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res. 2002;8(12):3702–3709.
   PubMed Web of Science ®Google Scholar
• Veldt BJ, van der Vliet HJ, von Blomberg BM, van Vlierberghe H, Gerken G, Nishi N, Hayashi K, Scheper RJ, de Knegt RJ, van den Eertwegh AJM, et al. Randomized placebo controlled phase I/II trial of alpha-galactosylceramide for the treatment of chronic hepatitis C. J Hepatol. 2007;47(3):356–365. doi:10.1016/j.jhep.2007.04.018.
   PubMed Web of Science ®Google Scholar
• Artiaga BL, Yang G, Hackmann TJ, Liu Q, Richt JA, Salek-Ardakani S, Castleman WL, Lednicky JA, Driver JP. alpha-Galactosylceramide protects swine against influenza infection when administered as a vaccine adjuvant. Sci Rep. 2016;6(1):23593. doi:10.1038/srep23593.
   PubMedGoogle Scholar
• Fotouhi F, Shaffifar M, Farahmand B, Shirian S, Saeidi M, Tabarraei A, Gorji A, Ghaemi A. Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus. Arch Virol. 2017;162(5):1251–1260. doi:10.1007/s00705-017-3230-7.
   PubMed Web of Science ®Google Scholar
• Tsao CC, Tsao PN, Chen YG, Chuang YH. Repeated activation of lung invariant NKT cells results in chronic obstructive pulmonary disease-like symptoms. PLoS One. 2016;11:e0147710. doi:10.1371/journal.pone.0147710.
   PubMed Web of Science ®Google Scholar
• Lee YJ, Wang H, Starrett GJ, Phuong V, Jameson SC, Hogquist KA. Tissue-specific distribution of iNKT cells impacts their cytokine response. Immunity. 2015;43(3):566–578. doi:10.1016/j.immuni.2015.06.025.
   PubMed Web of Science ®Google Scholar
• Stetson DB, Mohrs M, Reinhardt RL, Baron JL, Wang ZE, Gapin L, Kronenberg M, Locksley RM. Constitutive cytokine mRNAs mark natural killer (NK) and NK T cells poised for rapid effector function. J Exp Med. 2003;198:1069–1076. doi:10.1084/jem.20030630.
   PubMed Web of Science ®Google Scholar
• Westermann J, Pabst R. Distribution of lymphocyte subsets and natural killer cells in the human body. Clin Investig. 1992;70(7):539–544. doi:10.1007/BF00184787.
   PubMedGoogle Scholar
• Sprengers D, Sille FC, Derkow K, Besra GS, Janssen HL, Schott E, Boes M. Critical role for CD1d-restricted invariant NKT cells in stimulating intrahepatic CD8 T-cell responses to liver antigen. Gastroenterology. 2008;134(7):2132–2143. doi:10.1053/j.gastro.2008.02.037.
   PubMed Web of Science ®Google Scholar
• Coquet JM, Chakravarti S, Kyparissoudis K, McNab FW, Pitt LA, McKenzie BS, Berzins SP, Smyth MJ, Godfrey DI. Diverse cytokine production by NKT cell subsets and identification of an IL-17-producing CD4-NK1.1- NKT cell population. Proc Natl Acad Sci U S A. 2008;105(32):11287–11292. doi:10.1073/pnas.0801631105.
   PubMed Web of Science ®Google Scholar
• Crowe NY, Coquet JM, Berzins SP, Kyparissoudis K, Keating R, Pellicci DG, Hayakawa Y, Godfrey DI, Smyth MJ. Differential antitumor immunity mediated by NKT cell subsets in vivo. J Exp Med. 2005;202(9):1279–1288. doi:10.1084/jem.20050953.
   PubMed Web of Science ®Google Scholar
• Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, Albright A, Cheng JD, Kang SP, Shankaran V, et al. IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017;127:2930–2940. doi:10.1172/JCI91190.
   PubMed Web of Science ®Google Scholar